Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell’s Phase 3 Study in Metastatic Breast Cancer
The Data Safety Monitoring Board (DSMB) identified no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study of ...
manilatimes15d
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
pre-planned interim safety analysis conducted by an independent data and safety monitoring board (DSMB) for the ongoing Phase 3 EFZO-FIT™ study of the Company's lead therapeutic candidate, efzofitimod ...
manilatimes2d
Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast Cancer
The Data Safety Monitoring Board (DSMB) identified no safety concerns, and recommended continuation of BriaCell's pivotal Phase 3 study of Bria-IMT™ plus immune ... BriaCell's clinical advancement of ...